Navigation Links
Penn State Hershey Transplant Program Uses Assay to Monitor Cell-Mediated Immunity
Date:6/1/2008

Improvement Noted in Management of Transplant Recipients with Cancer

HERSHEY, Pa., June 1 /PRNewswire/ -- The management of immunosuppression in post-transplant patients with cancer is challenging. Clinicians must balance the need to treat the malignancy effectively while simultaneously monitoring the impact of chemotherapeutic agents on a patient's immune system.

Data relevant to improving management of such patients will be presented today at the American Transplant Congress in Toronto, Canada, from a cooperative study conducted by the Departments of Surgery and Pathology and the Division of Internal Medicine, Department of Medicine at the Penn State Milton S. Hershey Medical Center in Hershey, Pennsylvania.

Tadahiro Uemura, M.D., Ph.D. and his colleagues studied the immunosuppression status of 52 patients with post-transplant de novo malignancy, assessing the cell-mediated immunity of patients by taking advantage of the ability of the Cylex immune cell function assay (ImmuKnow(R)). They compared outcomes of patients who were and were not monitored using this assay over a follow-up period of nine months post-transplant. Their paper is entitled "Monitoring of immune function for treatment of post-transplant de novo malignancy." The 52 patients included 40 kidney transplants, 10 liver transplants, and two kidney and pancreas transplants. Uemura is an assistant professor, Division of Transplantation in the Department of Surgery at Penn State Hershey Medical Center.

The ImmuKnow cell function test measures cell-mediated immunity (CMI) by assaying the concentration of adenosine triphosphate (ATP) from CD4 cells following stimulation. The assay is intended for use in the detection of CMI in an immunosuppressed population.

According to Uemura and his collaborators, in patients previously diagnosed with cancer, levels of CMI were more precisely targeted toward 340 ng ATP/ml (within the "moderate" range of the ImmuKnow assay). However, for patients undergoing chemotherapy or radiation therapy for new malignancy post-transplant, there was a significant decrease in CMI despite a concurrent decrease in the levels of immunosuppressive medications. This suggests that patients' immune competencies change dramatically during active treatment of their cancer.

"It is clear that we can use the ImmuKnow cell function assay to manage immunosuppression more precisely in patients with new malignancy, post-transplant," stated Zakiyah Kadry, M.D., chief, Division of Transplantation, Department of Surgery and surgical director of the liver transplant program at Penn State Hershey Medical Center. "The test provides us with the ability to assess patients' immune status more accurately than the traditional monitoring of patients' levels of immunosuppressive drugs." she continued. Dr. Kadry is the senior author of this presentation.

About Penn State Milton S. Hershey Medical Center

Penn State Hershey Medical Center is one of the leading teaching and research hospitals in the country. The 501-bed Medical Center is a provider of high-level, patient-focused medical care. Annually the Medical Center admits more than 26,000 patients, accepts more than 766,000 outpatient visits, receives nearly 48,000 patients for emergency room visits and performs more than 23,000 surgical procedures. The Medical Center campus also includes Penn State College of Medicine (Penn State University's medical school), Penn State Hershey Cancer Institute, and Penn State Hershey Children's Hospital -- the region's only children's hospital.


'/>"/>
SOURCE Penn State Milton S. Hershey Medical Center
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Poniard Announces Positive First-Line Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in Patients with Metastatic Hormone Refractory Prostate Cancer
2. Prostate Cancer Treatment Offers Results Without Side Effects
3. New Gene Methylation Test for Prostate Cancer Available
4. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
5. CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence
6. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
7. Preventing Prostate Cancer and BPH: Prostate-Health Expert Available (National Mens Health Week Is June 9-15)
8. Alabama Hospitals Compare Infection Prevention Performance Statewide With New Benchmarking Tool
9. Statement From the Lupus Foundation of America Regarding the Release of Top-Line Results From a Study of Rituxan for the Treatment of Lupus
10. Vermillion and the Ohio State University Report That Novel Diagnostic Test May Help Predict Risk for Relapse of TTP, A Serious Blood Disorder
11. Free Prostate Cancer Seminar in Lake Ridge, VA: Dr. Charles Snuffy Myers Announces Vitamin D Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2016)... 2016 ReportsnReports.com adds Global ... Devices of its online business intelligence library. This ... current state of the Titrator industry. The report ... definitions, classifications, Specifications, applications and industry chain structure. ... Raw Material Suppliers, Equipment Suppliers, Manufacturing Cost Structure, ...
(Date:5/20/2016)... India , May 20, 2016 ... - Pipeline Review, H1 2016" market research report ... Plaque Psoriasis (Psoriasis Vulgaris), complete with comparative analysis ... mechanism of action (MoA), route of administration (RoA) ... featured news and press releases. It also reviews ...
(Date:5/19/2016)... According to a new market research report "Sunitinib Malate ... Germany , France , U.K., ... Japan )", published by MarketsandMarkets, The market is projected to ... from 2016 to 2021.      (Logo: http://photos.prnewswire.com/prnh/20160303/792302 ... through 26 Pages and in-depth TOC on "Sunitinib Malate ...
Breaking Medicine Technology:
(Date:5/23/2016)... ... May 23, 2016 , ... ComplianceOnline, the leading governance, risk and compliance ... summit on September 15 and 16, 2016 in San Diego, CA. The two ... bearers will be one of the largest gatherings of medical device companies, suppliers, professionals ...
(Date:5/23/2016)... ... May 23, 2016 , ... ... today that nominations will be accepted May 23, 2016 through August 5, ... include the Information Security Executive® of the Year, which recognizes executives who ...
(Date:5/23/2016)... ... May 23, 2016 , ... Hadley ... worldwide for people who are blind or visually impaired, announces the election of ... President Charles E. Young. Hadley’s Board of Trustees retained Morris & Berger, a ...
(Date:5/23/2016)... ... 23, 2016 , ... Octo Consulting Group, a leading provider of innovative information ... announce they have recently won two awards from AFCEA International. Octo was selected ... Year. Additionally, Octo VP of Civilian Affairs, Naina Leo, was named a winner of ...
(Date:5/23/2016)... , ... May 23, 2016 , ... VitreosHealth is presenting ... 10, 2016 from 11:00 AM – 12:00 PM ET. To register, click ... start a proactive outreach program built on Big Data with a new predictive and ...
Breaking Medicine News(10 mins):